Dramatic acquisitions and divestitures could reshape GSK, Novartis, Lilly, Valeant and Allergan

Article

Is a Pfizer-AstraZeneca merger in the offing?

Investment bankers on two continents were working overtime in the past several days as a flurry of transactions have been announced in the past 24 hours. The upshot: GSK will deepen its stake in consumer healthcare products by purchasing Novartis assets, while the latter will deepen its investment in oncology with GSK assets. Eli Lilly becomes the No. 2 animal health company worldwide by picking up GSK’s business there. Meanwhile, Valeant Pharma, having gobbled up Bausch+Lomb last year, has issued what could become a hostile takeover bid of Allergan. In an unusual move, it is allied with Pershing Capital, a “activist” investment firm led by William Ackman, which has already acquired 10% of Allergan. Usually, such activist investors take a position in a company, agitate for change, and then hope to benefit from either a friendly “white knight” acquirer or a restructuring of the target company. Ackman has stated that Pershing Capital will retain stock ownership in the eventual combined entity.

In after-hours trading on April 21, and after markets opened on April 22, all of the firms involved saw their shares rise—in Allergan’s case, by over 25%; typically, such a positive response means that the acquisitions and transactions will go through (barring governmental actions) without shareholder objection, although the dramatic price rise of Allergan could elicit other bidders.

Some details:

  • GSK is forming a joint company with Novartis, which will have majority-GSK ownership, for consumer healthcare, combining the GSK and Novartis assets.
  • GSK is buying Novartis’ vaccines business for $5.25-7.05 billion (depending on milestone payments. Novartis says that it will sell its flu vaccines business separately.
  • Novartis is buying GSK’s oncology portfolio for upwards of $16 billion (depending on clinical trial outcomes).
  • GSK expects annual cost savings of about $1.7 billion by the fifth year following closing, apportioned by 40% in consumer health, 40% in vaccines and 20% from divesting its oncology portfolio. Novartis did not identify cost savings, but noted that the GSK oncology products had 2013 sales of $1.6 billion, and has opt-in rights for GSK’s oncology pipeline products.
  • Eli Lilly is buying Novartis Animal Health for approximately $5.4 billion in an all-cash transaction; Lilly will fold this into its Elanco business. Lilly says that it will achieve annual cost savings of $200 million within three years of closing the deal.
  • Valeant and Pershing Capital are offering upwards of $15 billion in cash and a partial share-for-share trade for Allergan. Valeant says that it expects $2.7 billion in cost savings—with 80% achieved in the first six months after transaction completion. The combination will have significant portfolios in ophthalmology, dermatology and aesthetics (notably, Allergan’s Botox franchise); Valeant is also a major generics manufacturer.

The deal that has only been rumored about is Pfizer bidding $101 billion for AstraZeneca; according to various reports, the deal has been rejected by AZ. In the Valeant-Allergan deal, Valeant’s CEO, J. Michael Pearson, said that Allergan “made it clear, both privately and publicly, that they were unwilling to enter discussions with us about creating a value-enhancing combination.”

Valeant has a reputation for stripping acquired assets of what it considers non-essentials; in its bid, while noting that the combined company would be spending $300 million annually on Phase III R&D, Pearson also said that “The New Company will sell or eliminate Allergan’s earlier stage programs where Allergan’s track record has been largely unproductive.”

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.